CANCER FACT SHEET 2023
GASTRIC CANCER
ICD-10 C16.1-C16.9

Belgian Cancer Registry

CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative chance in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later (=200*1.05) and 255/100,000 over 5 years (=200*(1.05)^5).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

The net survival estimation was based on the regional lifetables 2023, obtained from Statbel.

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

GIST: Gastrointestinal stromal tumour

ADC: Adenocarcinoma

NENs: Neuroendocrine neoplasms

Cardia of stomach: is defined as C16.0 by ICD-10, and included in the Cancer Fact Sheet of oesophageal cancer

TABLE OF CONTENTS

1.1. Gastric cancer incidence: by region

1.1.1. Gastric cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2023

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Males																						
Belgium	0	0	0	1	0	0	3	8	14	19	27	31	55	57	52	75	75	55	11	4	487	9.1
	[0.0]	[0.0]	[0.0]	[0.3]	[0.0]	[0.0]	[0.8]	[2.1]	[3.6]	[5.1]	[6.8]	[7.7]	[14.7]	[17.9]	[19.5]	[36.9]	[60.1]	[69.0]	[35.1]	[66.0]	[8.5]	(8.3; 9.9)
Brussels	0	0	0	0	0	0	0	3	1	5	2	3	7	3	4	8	5	4	0	0	45	11.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[6.4]	[2.2]	[11.4]	[4.9]	[8.5]	[24.3]	[14.0]	[23.8]	[63.4]	[62.2]	[80.0]	[0.0]	[0.0]	[7.4]	(7.7; 14.3)
Flanders	0	0	0	1	0	0	3	2	7	8	14	18	24	32	29	43	55	41	8	4	289	8.6
	[0.0]	[0.0]	[0.0]	[0.5]	[0.0]	[0.0]	[1.4]	[0.9]	[3.2]	[3.8]	[6.1]	[7.4]	[10.5]	[16.3]	[17.7]	[33.0]	[66.7]	[76.2]	[38.5]	[100.8]	[8.6]	(7.6; 9.6)
Wallonia	0	0	0	0	0	0	0	3	6	6	11	10	24	22	19	24	15	10	3	0	153	9.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.6]	[5.1]	[5.1]	[8.8]	[8.0]	[20.5]	[21.8]	[22.2]	[39.8]	[43.6]	[47.8]	[36.5]	[0.0]	[8.5]	(7.8; 10.7)
Females																						
Belgium	0	1	0	1	2	1	4	10	12	17	22	33	40	44	51	66	51	45	18	2	420	6.6
	[0.0]	[0.3]	[0.0]	[0.3]	[0.6]	[0.3]	[1.0]	[2.6]	[3.1]	[4.6]	[5.7]	[8.3]	[10.5]	[13.0]	[17.2]	[26.9]	[29.3]	[33.6]	[25.4]	[9.6]	[7.1]	(5.9; 7.2)
Brussels	0	0	0	0	0	0	0	1	3	5	2	3	8	2	4	5	8	2	1	0	44	8.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.1]	[6.6]	[12.2]	[5.2]	[8.8]	[26.5]	[8.0]	[18.7]	[27.8]	[62.3]	[20.4]	[17.6]	[0.0]	[7.0]	(5.9; 11.0)

Region	N [CR]																				All ages	ESR2013 (95%CI)
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		
Flanders	0	0	0	0	2	1	2	8	4	8	13	17	22	19	27	39	29	30	12	1	234	6.0
	[0.0]	[0.0]	[0.0]	[0.0]	[1.1]	[0.5]	[0.9]	[3.8]	[1.8]	[3.8]	[5.8]	[7.2]	[9.6]	[9.4]	[15.4]	[26.0]	[26.5]	[35.2]	[27.3]	[8.2]	[6.8]	(5.2; 6.8)
Wallonia	0	1	0	1	0	0	2	1	5	4	7	13	10	23	20	22	14	13	5	1	142	7.0
	[0.0]	[1.0]	[0.0]	[0.9]	[0.0]	[0.0]	[1.7]	[0.8]	[4.2]	[3.4]	[5.6]	[10.3]	[8.1]	[20.6]	[20.0]	[28.4]	[27.0]	[33.6]	[23.6]	[15.4]	[7.6]	(5.9; 8.2)

1.2. Gastric cancer incidence: by tumour stage

1.2.1. Gastric cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

cStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	19 [0.6]	25 [2.6]	30 [6.7]	74 [1.3]	1.4 (1.0; 1.7)	19 [0.6]	17 [1.7]	21 [3.3]	57 [1.0]	0.9 (0.6; 1.1)
II	14 [0.4]	12 [1.3]	36 [8.1]	62 [1.1]	1.2 (0.9; 1.4)	10 [0.3]	13 [1.3]	30 [4.6]	53 [0.9]	0.8 (0.6; 1.0)
III	11 [0.3]	15 [1.6]	27 [6.1]	53 [0.9]	1.0 (0.7; 1.3)	4 [0.1]	6 [0.6]	14 [2.2]	24 [0.4]	0.4 (0.2; 0.5)
IV	22 [0.7]	41 [4.3]	55 [12.4]	118 [2.0]	2.2 (1.8; 2.6)	20 [0.6]	30 [2.9]	59 [9.1]	109 [1.8]	1.7 (1.3; 2.0)
X/NA	9 [0.3]	22 [2.3]	34 [7.6]	65 [1.1]	1.2 (0.9; 1.5)	13 [0.4]	18 [1.8]	26 [4.0]	57 [1.0]	0.9 (0.7; 1.1)

Note: Excluding gastrointestinal stromal tumours (GIST)

1.2.2. Gastric cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

pStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	22 [0.7]	25 [2.6]	27 [6.1]	74 [1.3]	1.3 (1.0; 1.6)	14 [0.4]	18 [1.8]	19 [2.9]	51 [0.9]	0.8 (0.6; 1.0)
II	11 [0.3]	10 [1.0]	22 [4.9]	43 [0.7]	0.8 (0.6; 1.0)	9 [0.3]	7 [0.7]	9 [1.4]	25 [0.4]	0.4 (0.2; 0.6)
III	12 [0.4]	9 [0.9]	25 [5.6]	46 [0.8]	0.9 (0.6; 1.1)	7 [0.2]	12 [1.2]	17 [2.6]	36 [0.6]	0.6 (0.4; 0.7)
IV	7 [0.2]	13 [1.4]	13 [2.9]	33 [0.6]	0.6 (0.4; 0.8)	8 [0.2]	15 [1.5]	17 [2.6]	40 [0.7]	0.6 (0.4; 0.8)
X/NA	23 [0.7]	58 [6.0]	95 [21.3]	176 [3.1]	3.4 (2.9; 3.9)	28 [0.8]	32 [3.1]	88 [13.6]	148 [2.5]	2.2 (1.8; 2.6)

Note: Excluding gastrointestinal stromal tumours (GIST)

1.2.3. Gastric cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

Stage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	22 [0.7]	31 [3.2]	28 [6.3]	81 [1.4]	1.5 (1.1; 1.8)	23 [0.7]	22 [2.2]	28 [4.3]	73 [1.2]	1.1 (0.9; 1.4)
II	14 [0.4]	11 [1.1]	41 [9.2]	66 [1.1]	1.2 (0.9; 1.5)	11 [0.3]	10 [1.0]	25 [3.9]	46 [0.8]	0.7 (0.5; 0.9)
III	14 [0.4]	16 [1.7]	36 [8.1]	66 [1.1]	1.2 (0.9; 1.5)	7 [0.2]	13 [1.3]	26 [4.0]	46 [0.8]	0.7 (0.5; 0.9)
IV	23 [0.7]	42 [4.4]	58 [13.0]	123 [2.1]	2.3 (1.9; 2.7)	20 [0.6]	32 [3.1]	60 [9.3]	112 [1.9]	1.7 (1.4; 2.0)
X/NA	2 [0.1]	15 [1.6]	19 [4.3]	36 [0.6]	0.7 (0.5; 0.9)	5 [0.2]	7 [0.7]	11 [1.7]	23 [0.4]	0.4 (0.2; 0.5)

Note: Excluding gastrointestinal stromal tumours (GIST)

1.3. Gastric cancer incidence: by tumour type

1.3.1. Gastric cancer incidence by type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

Type	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
GIST	28 [0.8]	49 [5.1]	38 [8.5]	115 [2.0]	2.1 (1.7; 2.5)	36 [1.1]	51 [5.0]	32 [5.0]	120 [2.0]	2.0 (1.6; 2.3)
ADC	59 [1.8]	91 [9.5]	164 [36.8]	314 [5.5]	5.9 (5.3; 6.6)	43 [1.3]	68 [6.7]	131 [20.3]	242 [4.1]	3.7 (3.2; 4.2)
NENs	15 [0.4]	16 [1.7]	11 [2.5]	42 [0.7]	0.8 (0.5; 1.0)	23 [0.7]	16 [1.6]	11 [1.7]	50 [0.8]	0.8 (0.6; 1.1)
Other	1 [0.0]	8 [0.8]	7 [1.6]	16 [0.3]	0.3 (0.2; 0.5)	0 [0.0]	0 [0.0]	8 [1.2]	8 [0.1]	0.1 (0.0; 0.2)

1.4. Gastric cancer incidence: by tumour type and tumour stage

1.4.1. Gastric cancer incidence by type, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

Type	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
ADC	I	11 [0.3]	22 [2.3]	21 [4.7]	54 [0.9]	1.0 (0.7; 1.3)	9 [0.3]	10 [1.0]	22 [3.4]	41 [0.7]	0.6 (0.4; 0.8)
	II	11 [0.3]	9 [0.9]	37 [8.3]	57 [1.0]	1.1 (0.8; 1.4)	9 [0.3]	10 [1.0]	23 [3.6]	42 [0.7]	0.6 (0.4; 0.8)
	III	13 [0.4]	14 [1.5]	35 [7.9]	62 [1.1]	1.2 (0.9; 1.5)	6 [0.2]	12 [1.2]	24 [3.7]	42 [0.7]	0.6 (0.4; 0.8)
	IV	23 [0.7]	40 [4.2]	55 [12.4]	118 [2.0]	2.2 (1.8; 2.6)	19 [0.6]	32 [3.1]	55 [8.5]	106 [1.8]	1.6 (1.3; 2.0)
	X/NA	1 [0.0]	6 [0.6]	16 [3.6]	23 [0.4]	0.5 (0.3; 0.7)	0 [0.0]	4 [0.4]	7 [1.1]	11 [0.2]	0.2 (0.1; 0.3)
NENs	I	11 [0.3]	8 [0.8]	6 [1.3]	25 [0.4]	0.4 (0.3; 0.6)	14 [0.4]	12 [1.2]	5 [0.8]	31 [0.5]	0.5 (0.3; 0.7)
	II	3 [0.1]	2 [0.2]	4 [0.9]	9 [0.2]	0.2 (0.1; 0.3)	2 [0.1]	0 [0.0]	1 [0.2]	3 [0.1]	0.0 (0.0; 0.1)
	III	1 [0.0]	1 [0.1]	1 [0.2]	3 [0.1]	0.1 (0.0; 0.1)	1 [0.0]	1 [0.1]	2 [0.3]	4 [0.1]	0.1 (0.0; 0.1)
	IV	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	1 [0.0]	0 [0.0]	1 [0.2]	2 [0.0]	0.0 (0.0; 0.1)
	X/NA	0 [0.0]	5 [0.5]	0 [0.0]	5 [0.1]	0.1 (0.0; 0.2)	5 [0.2]	3 [0.3]	2 [0.3]	10 [0.2]	0.2 (0.1; 0.3)
Other	I	0 [0.0]	1 [0.1]	1 [0.2]	2 [0.0]	0.0 (0.0; 0.1)	0 [0.0]	0 [0.0]	1 [0.2]	1 [0.0]	0.0 (0.0; 0.0)
	II	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	1 [0.2]	1 [0.0]	0.0 (0.0; 0.0)
	III	0 [0.0]	1 [0.1]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	IV	0 [0.0]	2 [0.2]	3 [0.7]	5 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	0 [0.0]	4 [0.6]	4 [0.1]	0.0 (0.0; 0.1)
	X/NA	1 [0.0]	4 [0.4]	3 [0.7]	8 [0.1]	0.2 (0.0; 0.3)	0 [0.0]	0 [0.0]	2 [0.3]	2 [0.0]	0.0 (0.0; 0.1)

Note: Excluding gastrointestinal stromal tumours (GIST)

Belgian Cancer Registry

2.1. Gastric cancer incidence trends: by region

2.1.1. Gastric cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	**N**	663	665	640	622	612	573	564	631	615	593	538	524	559	538	566	543	484	507	515	487		
	CR	13.0	13.0	12.4	12.0	11.7	10.9	10.6	11.7	11.4	10.9	9.8	9.5	10.1	9.7	10.1	9.6	8.6	8.9	9.0	8.5		
	ESR2013	17.8	17.5	17.1	15.3	15.2	14.2	13.3	14.6	14.1	13.4	11.6	11.2	11.6	11.2	11.5	10.8	9.5	9.8	9.7	9.1	-3.4 (-3.8; -3.1)	2004-2023
Brussels	**N**	55	57	59	60	53	42	50	63	54	49	55	48	57	47	52	59	50	46	43	45		
	CR	11.5	11.8	12.0	12.1	10.5	8.1	9.5	11.6	9.8	8.7	9.7	8.4	9.8	8.1	8.9	10.0	8.4	7.7	7.2	7.4		
	ESR2013	16.9	16.9	18.8	16.9	15.6	12.4	14.2	18.8	15.4	14.0	15.6	13.1	14.5	11.7	13.0	14.8	12.9	11.6	9.5	11.0	-2.4 (-3.3; -1.5)	2004-2023
Flanders	**N**	399	416	393	389	397	369	367	383	373	386	348	325	323	320	361	308	304	310	300	289		
	CR	13.4	14.0	13.1	12.9	13.1	12.0	11.9	12.3	11.9	12.2	11.0	10.2	10.1	9.9	11.1	9.4	9.3	9.4	9.0	8.6		
	ESR2013	17.8	18.4	17.1	15.9	16.2	15.2	14.2	14.1	14.0	14.3	12.3	11.2	10.9	10.9	11.8	9.8	9.6	9.5	9.1	8.6	-3.9 (-4.3; -3.5)	2004-2023
Wallonia	**N**	209	192	188	173	162	162	147	185	188	158	135	151	179	171	153	176	130	151	172	153		
	CR	12.7	11.7	11.3	10.4	9.7	9.6	8.6	10.8	10.9	9.1	7.7	8.6	10.2	9.7	8.6	9.9	7.3	8.5	9.6	8.5		
	ESR2013	18.0	15.8	16.7	13.7	13.2	12.8	11.2	14.5	14.0	11.4	9.1	10.4	12.1	11.7	10.1	11.7	8.3	9.7	10.9	9.3	-2.9 (-3.8; -1.9)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.1.2. Gastric cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	**N**	462	456	489	435	481	477	475	477	443	443	475	433	457	394	447	422	352	429	421	420		
	CR	8.7	8.5	9.1	8.1	8.8	8.7	8.6	8.5	7.9	7.8	8.4	7.6	8.0	6.8	7.7	7.3	6.0	7.3	7.2	7.1		
	ESR2013	8.7	8.4	8.8	7.9	8.5	8.4	8.1	8.1	7.4	7.4	8.0	7.1	7.5	6.4	7.2	6.7	5.6	6.9	6.6	6.6	-1.8 (-2.3; -1.3)	2004-2023
Brussels	**N**	30	36	29	37	57	51	48	37	38	43	51	35	53	45	67	45	52	49	42	44		
	CR	5.8	6.9	5.5	6.9	10.5	9.2	8.5	6.4	6.5	7.3	8.5	5.8	8.7	7.4	10.9	7.3	8.4	7.9	6.7	7.0		
	ESR2013	5.9	7.4	5.5	7.4	12.3	9.8	9.6	7.0	7.0	8.8	10.1	7.0	10.5	9.2	13.1	8.6	10.1	9.5	8.0	8.5	1.6 (-0.1; 3.3)	2004-2023
Flanders	**N**	302	298	311	271	280	306	291	279	280	261	282	273	259	233	231	253	201	248	244	234		
	CR	9.9	9.7	10.1	8.7	9.0	9.7	9.2	8.7	8.7	8.1	8.7	8.4	7.9	7.1	7.0	7.6	6.0	7.4	7.2	6.8		
	ESR2013	9.8	9.6	9.8	8.5	8.4	9.2	8.5	8.1	7.9	7.4	8.0	7.4	7.0	6.3	6.1	6.6	5.2	6.6	6.3	6.0	-2.8 (-3.3; -2.3)	2004-2023
Wallonia	**N**	130	122	149	127	144	120	136	161	125	139	142	125	145	116	149	124	99	132	135	142		
	CR	7.5	7.0	8.5	7.2	8.1	6.7	7.6	8.9	6.9	7.6	7.7	6.8	7.9	6.3	8.0	6.7	5.3	7.1	7.2	7.6		
	ESR2013	7.6	6.7	8.2	7.2	8.0	6.6	7.3	8.7	6.5	7.2	7.5	6.6	7.5	6.0	7.7	6.2	5.0	6.8	6.8	7.0	-0.9 (-1.8; 0.0)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Gastric cancer incidence trends: by tumour stage

2.2.1. Gastric cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2019-2023, including average annual percentage change from 2004 onwards

Stage		Males 2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period	Females 2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
I	N	98	77	81	94	81			84	56	79	80	73		
	CR	1.7	1.4	1.4	1.6	1.4			1.4	1.0	1.4	1.4	1.2		
	ESR2013	2.0	1.5	1.6	1.8	1.5	-3.5 (-4.7; -2.2)	2004-2023	1.3	0.9	1.3	1.3	1.1	-0.9 (-2.9; 1.1)	2004-2023
														-2.2 (-3.8; -0.5)	2004-2021
														10.2 (-9.7; 34.6)	2022-2023
II	N	70	65	60	76	66			44	43	54	63	46		
	CR	1.2	1.1	1.1	1.3	1.1			0.8	0.7	0.9	1.1	0.8		
	ESR2013	1.4	1.3	1.2	1.4	1.2	-0.6 (-2.0; 0.9)	2004-2023	0.7	0.7	0.8	0.9	0.7	0.2 (-1.2; 1.7)	2004-2023
							7.1 (3.0; 11.4)	2004-2012						5.8 (1.9; 9.9)	2004-2012
							-5.8 (-8.3; -3.2)	2013-2023						-3.6 (-6.2; -1.1)	2013-2023
III	N	76	58	65	53	66			49	41	36	37	46		
	CR	1.4	1.0	1.1	0.9	1.1			0.8	0.7	0.6	0.6	0.8		
	ESR2013	1.5	1.1	1.3	1.0	1.2	-3.1 (-4.4; -1.8)	2004-2023	0.8	0.6	0.6	0.6	0.7	-1.6 (-2.7; -0.5)	2004-2023
IV	N	157	158	148	145	123			92	90	115	96	112		
	CR	2.8	2.8	2.6	2.5	2.1			1.6	1.5	2.0	1.6	1.9		
	ESR2013	3.1	3.0	2.9	2.7	2.3	-2.0 (-2.8; -1.3)	2004-2023	1.5	1.5	1.9	1.5	1.7	-0.3 (-1.2; 0.6)	2004-2023
							-4.5 (-6.4; -2.7)	2004-2012							
							2.0 (-1.5; 5.5)	2013-2016							
							-1.4 (-3.6; 0.9)	2017-2023							
X/NA	N	48	38	28	39	36			48	42	27	27	23		

Stage	Males							Females						
	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
CR	0.9	0.7	0.5	0.7	0.6			0.8	0.7	0.5	0.5	0.4		
ESR2013	1.0	0.8	0.5	0.8	0.7	-12.1 (-13.3; -10.9)	2004-2023	0.7	0.6	0.4	0.4	0.4	-12.0 (-13.2; -10.8)	2004-2023
													-9.4 (-11.0; -7.7)	2004-2018
													-19.0 (-23.5; -14.2)	2019-2023

Note: Excluding gastrointestinal stromal tumours (GIST)

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Gastric cancer incidence trends: by tumour type

2.3.1. Gastric cancer incidence trends by type and sex: number of new diagnoses, crude and age-standardised incidence rates, 2019-2023, including average annual percentage change from 2004 onwards

Type		Males							Females						
		2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
GIST	N	94	88	125	108	115			105	80	118	118	120		
	CR	1.7	1.6	2.2	1.9	2.0			1.8	1.4	2.0	2.0	2.0		
	ESR2013	1.8	1.7	2.3	2.0	2.1	3.6 (2.8; 4.5)	2004-2023	1.8	1.3	1.9	2.0	2.0	5.2 (3.9; 6.4)	2004-2023
							6.2 (4.5; 7.9)	2004-2015						9.1 (6.4; 11.8)	2004-2014
							0.2 (-2.0; 2.5)	2016-2023						0.9 (-1.9; 3.8)	2015-2023
ADC	N	406	356	335	361	314			268	231	269	246	242		
	CR	7.2	6.3	5.9	6.3	5.5			4.6	4.0	4.6	4.2	4.1		
	ESR2013	8.2	7.0	6.5	6.9	5.9	-5.0 (-5.4; -4.5)	2004-2023	4.1	3.6	4.2	3.7	3.7	-3.9 (-4.4; -3.4)	2004-2023
NENs	N	32	26	34	34	42			41	35	37	44	50		
	CR	0.6	0.5	0.6	0.6	0.7			0.7	0.6	0.6	0.7	0.8		
	ESR2013	0.6	0.5	0.6	0.6	0.8	3.5 (1.8; 5.2)	2004-2023	0.7	0.6	0.6	0.7	0.8	3.3 (2.0; 4.6)	2004-2023
Other	N	11	14	13	12	16			8	6	5	13	8		
	CR	0.2	0.2	0.2	0.2	0.3			0.1	0.1	0.1	0.2	0.1		
	ESR2013	0.2	0.3	0.2	0.2	0.3	-2.6 (-4.2; -1.0)	2004-2023	0.1	0.1	0.1	0.2	0.1	-3.3 (-6.7; 0.2)	2004-2023
							-9.8 (-14.3; -5.1)	2004-2011							
							1.8 (-0.9; 4.7)	2012-2023							

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.4. Gastric cancer incidence trends: by age group

2.4.1. Gastric cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
15-59	N	119	140	99	115	103	103	109	118	116	119	96	111	131	123	123	89	83	102	112	103		
	CR	3.7	4.4	3.1	3.6	3.2	3.2	3.3	3.6	3.5	3.6	2.9	3.3	3.9	3.7	3.7	2.7	2.5	3.1	3.3	3.1		
	ESR2013	4.0	4.6	3.2	3.6	3.2	3.2	3.4	3.7	3.5	3.6	2.9	3.3	3.9	3.7	3.6	2.6	2.5	3.0	3.3	3.1	-1.3 (-2.3; -0.3)	2004-2023
60-74	N	264	260	240	234	223	204	194	237	238	223	213	199	196	172	203	217	206	180	196	164		
	CR	38.8	38.0	34.9	33.4	31.3	28.1	26.2	31.4	30.9	28.5	26.7	24.5	23.5	20.1	23.1	24.2	22.5	19.3	20.7	17.1		
	ESR2013	38.5	37.8	34.9	33.8	32.0	29.0	27.3	32.1	32.3	29.9	27.4	25.8	24.3	20.7	23.5	24.5	22.9	19.5	21.2	17.2	-3.5 (-4.1; -2.9)	2004-2023
75+	N	280	265	301	272	285	266	261	276	261	250	229	214	232	243	240	237	195	224	207	220		
	CR	95.5	87.5	95.8	83.5	84.6	77.0	73.7	76.4	70.7	66.5	59.7	54.7	58.8	61.6	60.4	58.7	47.2	53.8	48.0	49.4		
	ESR2013	101.3	95.7	105.3	84.2	88.4	83.7	75.9	79.5	74.9	70.9	60.2	55.6	58.6	63.0	60.8	57.9	47.3	53.1	47.6	49.2	-4.0 (-4.6; -3.5)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.4.2. Gastric cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
15-59	N	79	71	103	82	101	88	82	99	78	95	106	90	98	92	113	81	78	114	115	102		
	CR	2.5	2.3	3.2	2.6	3.2	2.7	2.5	3.0	2.4	2.9	3.2	2.7	3.0	2.8	3.4	2.5	2.4	3.5	3.5	3.1		
	ESR2013	2.6	2.3	3.3	2.6	3.2	2.8	2.6	3.1	2.4	2.9	3.2	2.7	3.0	2.8	3.4	2.5	2.4	3.4	3.5	3.1	0.7 (-0.3; 1.8)	2004-2023
60-74	N	137	138	125	136	129	140	131	134	120	127	150	122	146	128	140	141	116	152	143	135		
	CR	17.7	17.8	16.2	17.4	16.4	17.5	16.2	16.3	14.4	15.0	17.5	14.0	16.4	14.0	14.9	14.7	11.9	15.3	14.2	13.3		
	ESR2013	17.2	17.3	15.9	17.4	16.4	17.6	16.4	16.4	14.6	15.4	17.8	14.1	16.7	14.2	15.0	14.8	11.9	15.3	14.3	13.3	-1.3 (-1.9; -0.7)	2004-2023
75+	N	246	247	261	217	251	249	262	244	245	221	219	221	213	174	194	200	158	163	163	182		
	CR	47.3	46.5	47.9	38.9	44.1	43.1	44.7	41.1	40.8	36.6	35.9	35.8	34.6	28.4	31.7	32.6	25.5	26.3	25.7	28.2		
	ESR2013	48.1	46.9	47.7	39.2	43.9	43.1	43.7	40.5	39.4	35.4	35.7	35.5	33.4	27.4	30.5	30.9	24.8	26.0	24.8	28.1	-3.5 (-4.1; -3.0)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

3.1. Gastric cancer prevalence: by region

3.1.1. Gastric cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2023

Region		Males					Females				
		1-year	5-year	10-year	15-year	20-year	1-year	5-year	10-year	15-year	20-year
Belgium	N	392	1,326	2,132	2,609	2,933	335	1,183	1,995	2,533	2,840
	CR	6.8	22.9	36.8	45.0	50.6	5.6	19.8	33.4	42.5	47.6
	ESR2013	7.1	24.0	38.8	47.6	53.6	5.3	18.4	30.8	38.8	43.3
Brussels	N	38	134	210	246	281	35	126	225	272	298
	CR	6.2	21.9	34.3	40.2	45.9	5.5	19.8	35.3	42.7	46.8
	ESR2013	8.8	31.2	49.6	59.4	67.8	6.7	24.3	43.5	52.2	56.9
Flanders	N	234	772	1,224	1,510	1,704	181	666	1,115	1,425	1,622
	CR	6.9	22.9	36.2	44.7	50.5	5.3	19.3	32.4	41.4	47.1
	ESR2013	6.9	22.4	35.6	44.1	49.8	4.7	17.1	28.2	35.8	40.5
Wallonia	N	120	420	698	853	948	119	391	655	836	920
	CR	6.6	23.2	38.6	47.2	52.4	6.3	20.7	34.8	44.4	48.8
	ESR2013	7.1	25.0	41.8	51.4	57.2	5.8	19.3	32.2	40.8	44.8

Belgian Cancer Registry

4.1. Gastric cancer survival: by region

4.1.1. Gastric cancer survival by region, sex and age group: number at risk and net survival probabilities, 2014-2023

Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Net Survival Probability, 2014-2023						
Total	**All**	9,418	67.4% (66.4%; 68.5%)	51.1% (49.9%; 52.3%)	47.1% (45.7%; 48.4%)	46.2% (43.2%; 49.4%)
Males						
Belgium	**All ages**	5,214	66.0% (64.6%; 67.4%)	48.8% (47.2%; 50.4%)	44.1% (42.3%; 46.0%)	42.5% (38.2%; 47.3%)
	15-59	1,068	78.5% (76.0%; 81.0%)	60.4% (57.4%; 63.5%)	55.8% (52.6%; 59.1%)	52.7% (49.0%; 56.6%)
	60-74	1,931	72.0% (70.0%; 74.1%)	54.1% (51.8%; 56.6%)	49.2% (46.7%; 52.0%)	44.6% (40.4%; 49.2%)
	75+	2,216	54.8% (52.5%; 57.1%)	38.5% (35.9%; 41.2%)	34.0% (30.9%; 37.4%)	35.4% (26.8%; 46.7%)
Brussels	**All ages**	497	64.5% (60.3%; 69.1%)	48.5% (43.8%; 53.6%)	42.1% (37.1%; 47.8%)	39.9% (32.8%; 48.5%)
	15-59	170	74.2% (67.9%; 81.1%)	55.8% (48.6%; 63.9%)	51.9% (44.4%; 60.5%)	50.6% (42.7%; 60.1%)
	60-74	185	68.6% (62.1%; 75.9%)	54.1% (46.8%; 62.5%)	42.7% (35.0%; 52.0%)	35.9% (25.0%; 51.6%)
	75+	142	47.7% (39.6%; 57.4%)	32.7% (24.4%; 43.7%)	31.3% (22.0%; 44.5%)	33.6% (19.3%; 58.5%)
Flanders	**All ages**	3,160	64.9% (63.1%; 66.7%)	46.3% (44.3%; 48.5%)	42.8% (40.5%; 45.3%)	43.5% (37.4%; 50.7%)
	15-59	544	78.1% (74.7%; 81.7%)	59.4% (55.3%; 63.9%)	55.3% (51.0%; 60.1%)	52.0% (47.1%; 57.5%)
	60-74	1,103	72.1% (69.4%; 74.9%)	52.3% (49.2%; 55.7%)	49.2% (45.8%; 52.9%)	46.2% (40.6%; 52.5%)
	75+	1,513	54.8% (52.1%; 57.7%)	37.3% (34.2%; 40.6%)	33.7% (30.0%; 37.8%)	38.2% (26.7%; 54.6%)
Wallonia	**All ages**	1,557	68.8% (66.4%; 71.2%)	53.8% (51.0%; 56.7%)	47.4% (44.2%; 50.9%)	41.0% (35.3%; 47.6%)

Net Survival Probability, 2014-2023						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	15-59	354	81.1% (77.1%; 85.3%)	64.1% (59.1%; 69.5%)	58.4% (53.1%; 64.2%)	54.6% (48.2%; 61.9%)
	60-74	643	72.8% (69.4%; 76.4%)	57.3% (53.3%; 61.6%)	51.4% (47.0%; 56.1%)	43.9% (37.2%; 51.7%)
	75+	561	56.4% (52.0%; 61.1%)	43.2% (38.3%; 48.8%)	35.8% (29.7%; 43.2%)	29.0% (18.8%; 44.8%)
Females						
Belgium	All ages	4,204	69.2% (67.7%; 70.7%)	53.9% (52.2%; 55.7%)	50.7% (48.7%; 52.7%)	50.8% (46.9%; 55.0%)
	15-59	978	84.9% (82.7%; 87.2%)	68.6% (65.7%; 71.7%)	63.7% (60.6%; 67.1%)	61.1% (57.5%; 64.9%)
	60-74	1,354	76.1% (73.8%; 78.5%)	62.3% (59.6%; 65.1%)	58.6% (55.7%; 61.7%)	53.8% (49.5%; 58.5%)
	75+	1,873	56.1% (53.7%; 58.6%)	40.2% (37.5%; 43.1%)	38.2% (35.0%; 41.8%)	43.0% (35.3%; 52.3%)
Brussels	All ages	471	69.2% (65.0%; 73.7%)	53.1% (48.2%; 58.5%)	49.3% (43.9%; 55.4%)	60.2% (50.9%; 71.3%)
	15-59	153	83.7% (78.1%; 89.8%)	66.0% (58.7%; 74.2%)	59.6% (51.9%; 68.5%)	56.5% (48.3%; 66.1%)
	60-74	155	72.8% (66.0%; 80.3%)	59.6% (51.9%; 68.4%)	56.6% (48.5%; 66.1%)	46.7% (34.6%; 63.1%)
	75+	163	52.2% (44.5%; 61.1%)	34.9% (26.7%; 45.6%)	32.9% (23.2%; 46.5%)	64.7% (40.3%; 103.9%)
Flanders	All ages	2,436	68.8% (66.9%; 70.8%)	53.4% (51.1%; 55.8%)	50.2% (47.6%; 53.0%)	49.4% (43.9%; 55.6%)
	15-59	502	83.8% (80.7%; 87.2%)	68.0% (63.9%; 72.4%)	63.6% (59.2%; 68.3%)	61.4% (56.4%; 66.8%)
	60-74	739	76.2% (73.1%; 79.5%)	61.3% (57.6%; 65.1%)	57.2% (53.3%; 61.5%)	53.4% (47.6%; 59.9%)
	75+	1,196	58.0% (55.0%; 61.2%)	42.4% (39.0%; 46.2%)	40.3% (36.2%; 44.9%)	42.1% (32.7%; 54.1%)
Wallonia	All ages	1,297	69.9% (67.3%; 72.6%)	55.2% (52.1%; 58.3%)	52.1% (48.8%; 55.6%)	50.1% (44.9%; 55.9%)
	15-59	323	87.1% (83.5%; 90.9%)	70.8% (65.9%; 76.2%)	66.0% (60.6%; 71.8%)	62.9% (56.8%; 69.7%)
	60-74	460	77.0% (73.2%; 81.0%)	64.9% (60.4%; 69.7%)	61.5% (56.7%; 66.7%)	57.4% (51.3%; 64.3%)
	75+	514	52.9% (48.4%; 57.7%)	36.6% (31.7%; 42.3%)	34.9% (29.3%; 41.6%)	35.2% (24.6%; 50.2%)

4.2. Gastric cancer survival: by tumour stage

4.2.1. Gastric cancer survival by clinical stage (cStage) and sex: number at risk and net survival probabilities, 2014-2023

cStage	N at risk	Net Survival Probability, 2014-2023					
		1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	7,371	59.1% (58.0%; 60.3%)	45.3% (44.1%; 46.6%)	39.0% (37.7%; 40.3%)	35.6% (34.3%; 37.0%)	34.2% (32.8%; 35.7%)	30.4% (27.3%; 33.7%)
Males							
All	4,195	58.5% (56.9%; 60.1%)	43.9% (42.3%; 45.6%)	38.0% (36.3%; 39.7%)	34.5% (32.7%; 36.3%)	32.5% (30.7%; 34.5%)	25.3% (21.3%; 30.1%)
I	631	84.7% (81.5%; 88.1%)	76.9% (72.9%; 81.2%)	72.1% (67.4%; 77.0%)	70.1% (64.8%; 75.7%)	67.1% (60.8%; 73.9%)	53.4% (37.2%; 76.8%)
II	726	70.7% (67.2%; 74.4%)	55.3% (51.4%; 59.5%)	49.0% (44.9%; 53.4%)	44.7% (40.4%; 49.6%)	41.2% (36.6%; 46.5%)	33.7% (26.3%; 43.2%)
III	433	71.7% (67.2%; 76.4%)	55.9% (51.0%; 61.3%)	48.5% (43.4%; 54.3%)	42.9% (37.5%; 49.1%)	38.5% (32.6%; 45.6%)	38.7% (29.1%; 51.4%)
IV	1,328	33.6% (31.0%; 36.3%)	15.5% (13.5%; 17.7%)	8.9% (7.3%; 10.9%)	5.7% (4.4%; 7.5%)	4.9% (3.6%; 6.6%)	3.7% (2.2%; 6.3%)
X/NA	1,079	60.3% (57.2%; 63.6%)	47.0% (43.8%; 50.5%)	42.0% (38.6%; 45.7%)	38.7% (35.2%; 42.6%)	37.9% (34.2%; 42.0%)	27.1% (20.2%; 36.5%)
Females							
All	3,176	60.0% (58.3%; 61.8%)	47.1% (45.3%; 49.1%)	40.3% (38.4%; 42.4%)	37.2% (35.2%; 39.3%)	36.5% (34.4%; 38.7%)	36.9% (32.8%; 41.5%)
I	510	86.9% (83.6%; 90.4%)	78.3% (74.0%; 82.8%)	74.9% (70.0%; 80.1%)	72.2% (67.0%; 77.9%)	71.5% (65.6%; 77.9%)	76.5% (64.3%; 90.9%)
II	508	68.8% (64.6%; 73.2%)	54.2% (49.6%; 59.3%)	44.6% (39.9%; 49.9%)	42.1% (37.1%; 47.7%)	40.9% (35.7%; 46.9%)	33.7% (26.4%; 43.0%)
III	282	65.1% (59.6%; 71.2%)	48.2% (42.3%; 54.8%)	39.1% (33.1%; 46.0%)	29.9% (24.1%; 37.1%)	30.4% (24.4%; 37.9%)	30.6% (23.7%; 39.3%)
IV	880	32.4% (29.4%; 35.7%)	15.6% (13.3%; 18.3%)	9.6% (7.7%; 12.0%)	7.3% (5.6%; 9.6%)	6.1% (4.4%; 8.3%)	2.0% (0.5%; 7.5%)
X/NA	1,000	64.8% (61.7%; 68.1%)	55.0% (51.6%; 58.6%)	47.8% (44.2%; 51.7%)	44.8% (41.0%; 48.9%)	44.4% (40.5%; 48.7%)	48.5% (40.7%; 57.8%)

Note: Excluding gastrointestinal stromal tumours (GIST)

4.2.2. Gastric cancer survival by pathological stage (pStage), and sex: number at risk and net survival probabilities, 2014-2023

pStage	N at risk	Net Survival Probability, 2014-2023					
		1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	7,371	59.1% (58.0%; 60.3%)	45.3% (44.1%; 46.6%)	39.0% (37.7%; 40.3%)	35.6% (34.3%; 37.0%)	34.2% (32.8%; 35.7%)	30.4% (27.3%; 33.7%)
Males							
All	4,195	58.5% (56.9%; 60.1%)	43.9% (42.3%; 45.6%)	38.0% (36.3%; 39.7%)	34.5% (32.7%; 36.3%)	32.5% (30.7%; 34.5%)	25.3% (21.3%; 30.1%)
I	702	94.1% (91.8%; 96.5%)	91.8% (88.7%; 94.9%)	88.9% (85.1%; 92.8%)	86.8% (82.3%; 91.6%)	84.4% (79.0%; 90.2%)	63.4% (48.3%; 83.2%)
II	513	88.7% (85.6%; 92.0%)	76.8% (72.5%; 81.4%)	69.6% (64.7%; 74.9%)	65.8% (60.4%; 71.8%)	61.7% (55.6%; 68.6%)	46.8% (36.0%; 60.8%)
III	551	73.9% (70.0%; 77.9%)	50.2% (45.8%; 55.0%)	38.4% (34.0%; 43.3%)	29.0% (24.7%; 34.1%)	23.7% (19.5%; 28.8%)	21.4% (16.4%; 27.9%)
IV	395	37.4% (32.8%; 42.6%)	15.2% (12.0%; 19.4%)	6.9% (4.7%; 10.2%)	4.1% (2.4%; 6.8%)	3.1% (1.7%; 5.8%)	3.5% (1.8%; 6.7%)
X/NA	2,035	38.4% (36.3%; 40.7%)	22.9% (21.0%; 25.0%)	18.3% (16.4%; 20.4%)	15.9% (14.0%; 18.1%)	15.6% (13.6%; 17.8%)	12.5% (8.2%; 19.0%)
Females							
All	3,176	60.0% (58.3%; 61.8%)	47.1% (45.3%; 49.1%)	40.3% (38.4%; 42.4%)	37.2% (35.2%; 39.3%)	36.5% (34.4%; 38.7%)	36.9% (32.8%; 41.5%)
I	550	97.2% (95.2%; 99.2%)	96.3% (93.6%; 99.1%)	94.5% (90.9%; 98.2%)	93.3% (89.0%; 97.7%)	94.0% (89.0%; 99.4%)	88.1% (71.0%; 109.4%)
II	352	90.3% (86.8%; 93.9%)	79.1% (74.3%; 84.2%)	72.9% (67.5%; 78.8%)	67.9% (61.8%; 74.5%)	66.5% (60.0%; 73.7%)	78.2% (66.1%; 92.6%)
III	369	72.5% (67.8%; 77.5%)	52.6% (47.4%; 58.4%)	36.1% (30.9%; 42.0%)	26.9% (21.9%; 33.1%)	27.2% (22.0%; 33.5%)	16.7% (11.1%; 24.9%)
IV	337	44.5% (39.4%; 50.2%)	20.1% (16.2%; 25.1%)	13.5% (10.1%; 18.1%)	10.0% (7.1%; 14.3%)	8.2% (5.4%; 12.3%)	4.1% (1.7%; 9.9%)
X/NA	1,572	40.7% (38.3%; 43.4%)	27.3% (24.9%; 29.8%)	20.7% (18.5%; 23.2%)	18.7% (16.4%; 21.2%)	17.7% (15.4%; 20.3%)	20.1% (16.6%; 24.5%)

Note: Excluding gastrointestinal stromal tumours (GIST)

4.2.3. Gastric cancer survival by stage and sex: number at risk and net survival probabilities, 2014-2023

Stage	N at risk	**Net Survival Probability, 2014-2023**					
		1-y (95%CI)	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	7,371	59.1% (58.0%; 60.3%)	45.3% (44.1%; 46.6%)	39.0% (37.7%; 40.3%)	35.6% (34.3%; 37.0%)	34.2% (32.8%; 35.7%)	30.4% (27.3%; 33.7%)
Males							
All	4,195	58.5% (56.9%; 60.1%)	43.9% (42.3%; 45.6%)	38.0% (36.3%; 39.7%)	34.5% (32.7%; 36.3%)	32.5% (30.7%; 34.5%)	25.3% (21.3%; 30.1%)
I	796	88.2% (85.5%; 91.0%)	83.0% (79.6%; 86.5%)	79.1% (75.1%; 83.3%)	77.7% (73.1%; 82.5%)	75.8% (70.4%; 81.6%)	53.4% (38.2%; 74.5%)
II	764	74.7% (71.4%; 78.2%)	61.9% (58.1%; 66.0%)	54.9% (50.9%; 59.3%)	51.6% (47.2%; 56.3%)	48.2% (43.4%; 53.5%)	36.5% (29.0%; 46.1%)
III	666	70.7% (67.0%; 74.5%)	49.7% (45.7%; 54.1%)	41.2% (37.1%; 45.8%)	34.1% (29.8%; 38.9%)	30.1% (25.8%; 35.1%)	28.2% (21.9%; 36.3%)
IV	1,422	33.7% (31.2%; 36.3%)	15.4% (13.5%; 17.6%)	8.8% (7.3%; 10.7%)	5.7% (4.4%; 7.4%)	4.9% (3.6%; 6.5%)	4.0% (2.5%; 6.4%)
X/NA	550	42.2% (38.0%; 46.9%)	28.8% (24.8%; 33.4%)	26.0% (22.0%; 30.8%)	23.2% (19.1%; 28.1%)	22.9% (18.7%; 28.0%)	22.8% (16.7%; 31.2%)
Females							
All	3,176	60.0% (58.3%; 61.8%)	47.1% (45.3%; 49.1%)	40.3% (38.4%; 42.4%)	37.2% (35.2%; 39.3%)	36.5% (34.4%; 38.7%)	36.9% (32.8%; 41.5%)
I	665	89.7% (87.0%; 92.5%)	85.9% (82.4%; 89.4%)	82.5% (78.4%; 86.8%)	81.3% (76.8%; 86.1%)	81.4% (76.2%; 86.9%)	77.5% (62.8%; 95.7%)
II	541	75.0% (71.2%; 79.1%)	60.9% (56.4%; 65.7%)	53.4% (48.8%; 58.6%)	51.0% (46.1%; 56.4%)	49.2% (44.1%; 55.0%)	57.0% (48.3%; 67.2%)
III	459	67.9% (63.5%; 72.6%)	49.9% (45.2%; 55.1%)	37.5% (32.7%; 42.9%)	28.1% (23.4%; 33.7%)	29.3% (24.4%; 35.1%)	22.0% (15.7%; 30.9%)
IV	955	32.6% (29.7%; 35.8%)	15.6% (13.4%; 18.2%)	9.6% (7.8%; 11.9%)	7.2% (5.6%; 9.4%)	5.9% (4.4%; 8.0%)	2.4% (0.8%; 7.5%)
X/NA	559	50.5% (46.3%; 55.2%)	39.2% (34.9%; 44.1%)	32.0% (27.7%; 37.0%)	29.2% (24.8%; 34.3%)	28.3% (23.9%; 33.5%)	32.4% (26.5%; 39.7%)

Note: Excluding gastrointestinal stromal tumours (GIST)

4.3. Gastric cancer survival: by tumour type and tumour stage

4.3.1. Gastric cancer survival by type, stage and sex: number at risk and net survival probabilities, 2014-2023

Type	Stage	N at risk	Net Survival Probability, 2014-2023 1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total		9,418	67.4% (66.4%; 68.5%)	56.3% (55.2%; 57.4%)	51.1% (49.9%; 52.3%)	48.2% (46.9%; 49.5%)	47.1% (45.7%; 48.4%)	46.2% (43.2%; 49.4%)
Males								
GIST	All	1,046	96.8% (95.3%; 98.3%)	94.1% (91.9%; 96.3%)	92.2% (89.6%; 95.0%)	91.2% (88.1%; 94.4%)	90.8% (87.1%; 94.6%)	111.5% (100.6%; 123.6%)
ADC	All	3,766	56.7% (55.0%; 58.4%)	41.1% (39.4%; 42.9%)	35.0% (33.2%; 36.8%)	31.3% (29.5%; 33.2%)	29.2% (27.3%; 31.2%)	21.6% (17.7%; 26.4%)
	I	655	86.1% (82.9%; 89.3%)	80.0% (76.1%; 84.1%)	75.9% (71.3%; 80.7%)	74.2% (69.0%; 79.8%)	71.9% (65.8%; 78.5%)	48.4% (32.9%; 71.1%)
	II	709	74.3% (70.9%; 77.9%)	61.2% (57.3%; 65.4%)	53.8% (49.6%; 58.4%)	50.4% (45.9%; 55.4%)	46.8% (41.9%; 52.3%)	35.5% (27.8%; 45.2%)
	III	647	70.4% (66.7%; 74.3%)	48.8% (44.7%; 53.2%)	40.6% (36.4%; 45.3%)	33.5% (29.2%; 38.3%)	29.5% (25.1%; 34.5%)	27.3% (20.9%; 35.5%)
	IV	1,337	34.0% (31.5%; 36.7%)	15.3% (13.3%; 17.5%)	8.8% (7.2%; 10.7%)	5.7% (4.3%; 7.4%)	4.7% (3.5%; 6.4%)	3.7% (2.3%; 6.2%)
	X/NA	418	31.8% (27.4%; 37.0%)	16.2% (12.6%; 20.8%)	13.2% (9.8%; 17.6%)	9.5% (6.5%; 14.0%)	9.4% (6.3%; 14.0%)	6.9% (3.5%; 13.8%)
NENs	All	310	87.3% (83.3%; 91.5%)	81.9% (77.1%; 87.1%)	78.4% (72.9%; 84.2%)	76.3% (70.4%; 82.8%)	77.3% (70.9%; 84.4%)	79.6% (66.0%; 96.1%)
	I	127	99.8% (97.1%; 102.6%)	98.5% (94.0%; 103.2%)	96.8% (90.9%; 103.0%)	95.7% (88.5%; 103.4%)	96.2% (87.6%; 105.7%)	93.1% (71.1%; 121.8%)
	II	42	N<50	N<50	N<50	N<50	N<50	N<50
	III	13	N<50	N<50	N<50	N<50	N<50	N<50
	IV	42	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	87	87.7% (80.3%; 95.7%)	80.5% (71.4%; 90.8%)	81.2% (71.4%; 92.3%)	79.0% (68.1%; 91.8%)	80.8% (68.9%; 94.7%)	89.0% (64.4%; 123.0%)
Other	All	121	41.1% (32.8%; 51.5%)	34.5% (26.2%; 45.5%)	29.1% (20.6%; 41.2%)	28.3% (19.5%; 41.0%)	26.2% (17.3%; 39.8%)	21.4% (8.5%; 53.7%)
	I	14	N<50	N<50	N<50	N<50	N<50	N<50
	II	13	N<50	N<50	N<50	N<50	N<50	N<50
	III	6	N<50	N<50	N<50	N<50	N<50	N<50
	IV	43	N<50	N<50	N<50	N<50	N<50	N<50

Type	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
			Net Survival Probability, 2014-2023					
	X/NA	45	N<50	N<50	N<50	N<50	N<50	N<50
Females								
GIST	All	1,050	97.6% (96.2%; 98.9%)	96.5% (94.8%; 98.3%)	95.7% (93.5%; 97.9%)	94.4% (91.5%; 97.3%)	94.7% (91.4%; 98.2%)	94.3% (85.7%; 103.7%)
ADC	All	2,702	56.3% (54.3%; 58.3%)	41.4% (39.4%; 43.5%)	33.8% (31.8%; 35.9%)	30.2% (28.1%; 32.3%)	29.3% (27.2%; 31.6%)	30.7% (26.4%; 35.7%)
	I	470	86.9% (83.4%; 90.6%)	81.4% (77.0%; 86.1%)	76.4% (71.2%; 82.1%)	74.9% (69.2%; 81.1%)	73.6% (67.1%; 80.7%)	71.9% (55.3%; 93.5%)
	II	500	74.2% (70.2%; 78.4%)	59.4% (54.7%; 64.4%)	51.1% (46.2%; 56.4%)	48.6% (43.5%; 54.2%)	47.1% (41.8%; 53.1%)	54.5% (45.6%; 65.2%)
	III	441	68.3% (63.9%; 73.1%)	49.6% (44.8%; 54.9%)	36.6% (31.8%; 42.2%)	26.8% (22.1%; 32.5%)	27.9% (23.0%; 33.8%)	20.6% (14.5%; 29.2%)
	IV	912	33.1% (30.2%; 36.4%)	15.5% (13.3%; 18.2%)	9.3% (7.4%; 11.6%)	6.9% (5.3%; 9.1%)	5.6% (4.1%; 7.7%)	2.3% (0.7%; 7.1%)
	X/NA	379	36.0% (31.2%; 41.6%)	20.5% (16.3%; 25.7%)	12.8% (9.2%; 17.9%)	8.5% (5.4%; 13.2%)	8.1% (5.0%; 13.0%)	14.7% (9.0%; 24.2%)
NENs	All	387	91.7% (88.7%; 94.7%)	90.9% (87.6%; 94.3%)	89.6% (85.8%; 93.5%)	89.1% (85.0%; 93.5%)	88.8% (84.1%; 93.7%)	81.3% (70.3%; 94.1%)
	I	189	98.2% (95.7%; 100.8%)	98.3% (95.2%; 101.5%)	99.7% (96.2%; 103.3%)	98.9% (94.2%; 103.9%)	102.3% (97.3%; 107.4%)	88.0% (66.7%; 116.1%)
	II	31	N<50	N<50	N<50	N<50	N<50	N<50
	III	13	N<50	N<50	N<50	N<50	N<50	N<50
	IV	20	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	134	93.1% (88.5%; 98.0%)	92.9% (87.7%; 98.4%)	87.2% (80.5%; 94.4%)	87.3% (80.3%; 95.0%)	85.3% (77.4%; 94.0%)	78.5% (65.2%; 94.4%)
Other	All	93	39.3% (30.0%; 51.5%)	33.5% (24.3%; 46.2%)	30.6% (21.2%; 44.1%)	31.6% (21.5%; 46.4%)	34.0% (23.0%; 50.4%)	27.7% (13.0%; 58.9%)
	I	8	N<50	N<50	N<50	N<50	N<50	N<50
	II	11	N<50	N<50	N<50	N<50	N<50	N<50
	III	5	N<50	N<50	N<50	N<50	N<50	N<50
	IV	23	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	46	N<50	N<50	N<50	N<50	N<50	N<50

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Belgian Cancer Registry

5.1. Gastric cancer survival trends: by tumour stage

5.1.1. Gastric cancer survival trends by stage and sex: number at risk and net survival probabilities, 2004-2023

		Males				Females			
		N at risk	Net Survival Probability			N at risk	Net Survival Probability		
Period	Stage		1-y (95%CI)	3-y (95%CI)	5-y (95%CI)		1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2008	**All**	2,905	50.5% (48.6%; 52.4%)	31.8% (29.9%; 33.7%)	28.6% (26.6%; 30.7%)	2,079	50.7% (48.5%; 53.0%)	34.6% (32.3%; 37.0%)	30.0% (27.6%; 32.6%)
	I	537	85.7% (82.3%; 89.3%)	77.7% (73.2%; 82.6%)	74.4% (68.9%; 80.3%)	394	82.6% (78.5%; 86.9%)	75.2% (69.9%; 81.0%)	70.3% (63.8%; 77.5%)
	II	306	83.0% (78.4%; 88.0%)	59.5% (53.2%; 66.4%)	52.3% (45.4%; 60.3%)	211	72.3% (66.1%; 79.1%)	52.3% (45.1%; 60.8%)	44.2% (36.8%; 53.2%)
	III	393	60.9% (56.0%; 66.2%)	29.6% (25.0%; 35.1%)	23.5% (18.9%; 29.2%)	228	55.0% (48.7%; 62.2%)	24.8% (19.4%; 31.6%)	18.6% (13.4%; 25.9%)
	IV	722	28.2% (25.0%; 31.8%)	5.4% (3.9%; 7.4%)	4.0% (2.7%; 6.0%)	448	28.8% (24.8%; 33.4%)	6.2% (4.3%; 9.0%)	3.6% (2.2%; 6.0%)
	X/NA	947	32.6% (29.6%; 35.9%)	17.7% (15.1%; 20.7%)	15.8% (13.2%; 18.9%)	798	40.4% (36.9%; 44.1%)	28.5% (25.1%; 32.4%)	24.4% (20.8%; 28.6%)
2009-2013	**All**	2,599	53.8% (51.8%; 55.9%)	32.4% (30.5%; 34.6%)	28.3% (26.2%; 30.5%)	1,946	55.0% (52.7%; 57.3%)	37.2% (34.9%; 39.7%)	32.9% (30.4%; 35.5%)
	I	471	82.9% (79.0%; 86.9%)	71.6% (66.4%; 77.1%)	70.1% (64.1%; 76.7%)	389	88.6% (84.9%; 92.5%)	77.7% (72.3%; 83.5%)	75.1% (68.5%; 82.2%)
	II	484	75.1% (71.0%; 79.4%)	51.8% (47.0%; 57.2%)	45.2% (40.0%; 51.1%)	309	75.1% (70.1%; 80.5%)	56.8% (50.7%; 63.6%)	50.5% (43.6%; 58.3%)
	III	413	63.9% (59.1%; 69.0%)	30.1% (25.6%; 35.4%)	19.5% (15.7%; 24.4%)	254	60.9% (54.9%; 67.5%)	31.1% (25.5%; 37.9%)	23.1% (18.0%; 29.8%)
	IV	648	29.5% (26.1%; 33.3%)	5.8% (4.2%; 8.1%)	3.5% (2.2%; 5.5%)	462	25.4% (21.7%; 29.8%)	5.5% (3.7%; 8.2%)	3.2% (1.8%; 5.6%)
	X/NA	583	32.5% (28.7%; 36.8%)	15.8% (12.7%; 19.7%)	13.9% (10.7%; 18.2%)	533	41.6% (37.4%; 46.2%)	26.7% (22.8%; 31.4%)	22.2% (18.3%; 27.0%)
2014-2018	**All**	2,198	56.1% (53.9%; 58.3%)	35.8% (33.6%; 38.1%)	31.4% (29.0%; 33.9%)	1,680	59.4% (57.0%; 62.0%)	39.1% (36.5%; 41.8%)	35.3% (32.6%; 38.1%)
	I	366	88.1% (84.2%; 92.3%)	78.0% (72.2%; 84.4%)	76.2% (69.1%; 84.0%)	295	90.9% (87.0%; 95.0%)	85.3% (79.7%; 91.2%)	85.3% (78.5%; 92.7%)
	II	429	72.2% (67.7%; 76.9%)	51.2% (46.1%; 57.0%)	47.6% (41.9%; 54.1%)	292	78.4% (73.4%; 83.7%)	56.6% (50.4%; 63.5%)	52.9% (46.3%; 60.5%)

Period	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability		
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	III	349	69.4% (64.3%; 74.8%)	37.7% (32.4%; 43.9%)	26.9% (21.8%; 33.2%)	250	68.4% (62.7%; 74.8%)	34.0% (28.2%; 41.1%)	24.1% (18.7%; 31.0%)
	IV	691	29.6% (26.3%; 33.3%)	7.0% (5.2%; 9.5%)	3.5% (2.2%; 5.4%)	450	31.6% (27.5%; 36.3%)	9.3% (6.9%; 12.6%)	6.5% (4.5%; 9.5%)
	X/NA	365	42.5% (37.4%; 48.2%)	27.8% (22.9%; 33.7%)	24.5% (19.5%; 30.9%)	394	47.9% (42.9%; 53.4%)	28.7% (23.9%; 34.4%)	24.5% (19.8%; 30.2%)
2019-2023	All	1,997	61.1% (58.9%; 63.4%)	40.5% (38.0%; 43.1%)	33.1% (30.0%; 36.6%)	1,497	60.7% (58.2%; 63.4%)	41.9% (39.0%; 45.0%)	38.0% (34.5%; 41.8%)
	I	430	88.3% (84.7%; 92.0%)	80.3% (75.0%; 85.9%)	73.7% (64.7%; 83.9%)	371	88.8% (85.0%; 92.7%)	79.9% (74.1%; 86.2%)	76.1% (67.8%; 85.4%)
	II	335	78.0% (73.2%; 83.1%)	60.2% (54.0%; 67.2%)	45.4% (37.1%; 55.5%)	249	71.1% (65.3%; 77.4%)	50.0% (43.2%; 57.9%)	45.0% (36.9%; 54.8%)
	III	317	72.1% (66.9%; 77.7%)	45.3% (39.1%; 52.5%)	35.2% (28.2%; 43.8%)	209	67.3% (60.8%; 74.4%)	42.8% (35.4%; 51.8%)	40.7% (32.3%; 51.3%)
	IV	731	37.5% (34.1%; 41.3%)	10.7% (8.4%; 13.6%)	6.8% (4.7%; 9.7%)	505	33.6% (29.6%; 38.0%)	9.7% (7.2%; 13.1%)	4.0% (2.2%; 7.6%)
	X/NA	185	41.8% (34.8%; 50.3%)	22.2% (15.9%; 31.2%)	18.1% (11.2%; 29.1%)	165	56.9% (49.3%; 65.7%)	40.2% (31.6%; 51.1%)	39.9% (30.5%; 52.2%)

Note: Excluding gastrointestinal stromal tumours (GIST)

5.2. Gastric cancer survival trends: by tumour type and tumour stage

5.2.1. Gastric cancer survival trends by type, stage and sex: number at risk and net survival probabilities, 2004-2023

Type	Period	Stage	Males				Females			
				Net Survival Probability				Net Survival Probability		
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
GIST	2004-2008	All	262	98.0% (95.1%; 100.9%)	95.7% (90.7%; 101.0%)	97.7% (91.5%; 104.4%)	236	97.4% (94.6%; 100.4%)	94.8% (90.1%; 99.7%)	96.4% (90.7%; 102.6%)
	2009-2013	All	358	93.7% (90.6%; 96.9%)	92.5% (88.0%; 97.1%)	93.2% (87.5%; 99.2%)	355	96.1% (93.5%; 98.7%)	94.9% (91.1%; 98.8%)	96.6% (92.0%; 101.5%)
	2014-2018	All	520	94.9% (92.5%; 97.3%)	92.8% (89.3%; 96.5%)	92.9% (88.5%; 97.6%)	513	97.0% (95.0%; 99.1%)	94.3% (91.1%; 97.7%)	93.5% (89.0%; 98.2%)
	2019-2023	All	526	98.7% (96.8%; 100.5%)	91.3% (87.4%; 95.5%)	86.0% (78.8%; 93.8%)	537	98.1% (96.4%; 99.8%)	97.1% (94.2%; 100.0%)	96.9% (92.3%; 101.7%)
ADC	2004-2008	All	2,756	50.7% (48.8%; 52.7%)	31.4% (29.5%; 33.4%)	28.1% (26.1%; 30.2%)	1,917	48.7% (46.4%; 51.1%)	31.9% (29.6%; 34.3%)	27.3% (24.9%; 29.9%)
		I	519	85.4% (81.9%; 89.0%)	77.3% (72.7%; 82.3%)	74.1% (68.5%; 80.2%)	369	82.1% (77.8%; 86.6%)	74.9% (69.3%; 80.8%)	69.6% (62.8%; 77.2%)
		II	304	82.9% (78.2%; 87.9%)	59.9% (53.6%; 66.9%)	52.7% (45.7%; 60.6%)	207	72.8% (66.5%; 79.6%)	53.4% (46.0%; 61.9%)	45.1% (37.6%; 54.2%)
		III	386	61.4% (56.5%; 66.8%)	29.6% (25.0%; 35.1%)	23.6% (19.0%; 29.4%)	227	55.3% (48.9%; 62.5%)	24.9% (19.5%; 31.8%)	18.7% (13.5%; 26.0%)
		IV	689	29.2% (25.9%; 32.9%)	5.6% (4.1%; 7.7%)	4.2% (2.8%; 6.3%)	432	28.4% (24.4%; 33.1%)	5.8% (3.9%; 8.5%)	3.0% (1.7%; 5.3%)
		X/NA	858	30.8% (27.7%; 34.2%)	15.0% (12.4%; 18.0%)	12.6% (10.1%; 15.7%)	682	33.9% (30.4%; 37.9%)	21.0% (17.7%; 24.9%)	17.2% (13.8%; 21.4%)
	2009-2013	All	2,447	53.0% (51.0%; 55.2%)	31.2% (29.2%; 33.4%)	27.0% (25.0%; 29.3%)	1,741	52.9% (50.5%; 55.4%)	33.9% (31.4%; 36.5%)	29.5% (26.9%; 32.3%)
		I	442	82.7% (78.8%; 86.9%)	71.2% (65.8%; 77.0%)	69.9% (63.7%; 76.8%)	330	87.6% (83.4%; 92.0%)	76.2% (70.2%; 82.7%)	73.2% (65.9%; 81.2%)
		II	462	76.2% (72.1%; 80.6%)	52.5% (47.5%; 58.0%)	45.7% (40.3%; 51.7%)	296	76.3% (71.2%; 81.8%)	57.0% (50.8%; 64.0%)	51.2% (44.2%; 59.3%)
		III	406	63.7% (58.9%; 68.9%)	29.9% (25.3%; 35.2%)	19.6% (15.7%; 24.6%)	246	60.8% (54.7%; 67.5%)	30.4% (24.8%; 37.3%)	22.2% (17.0%; 28.9%)
		IV	622	28.7% (25.2%; 32.6%)	5.4% (3.8%; 7.6%)	3.0% (1.8%; 5.0%)	435	26.3% (22.4%; 30.8%)	5.9% (4.0%; 8.7%)	3.4% (2.0%; 5.9%)
		X/NA	515	27.7% (23.9%; 32.1%)	10.1% (7.4%; 13.7%)	8.2% (5.5%; 12.2%)	434	32.7% (28.4%; 37.8%)	15.7% (12.3%; 20.2%)	11.6% (8.3%; 16.2%)
	2014-2018	All	2,000	54.5% (52.2%; 56.9%)	32.8% (30.6%; 35.3%)	28.0% (25.6%; 30.6%)	1,448	56.2% (53.5%; 58.9%)	33.5% (30.9%; 36.3%)	29.3% (26.6%; 32.3%)
		I	320	87.0% (82.7%; 91.6%)	75.0% (68.5%; 82.0%)	72.1% (64.3%; 80.8%)	226	89.5% (84.7%; 94.5%)	81.8% (75.0%; 89.1%)	80.8% (72.6%; 89.9%)
		II	406	71.8% (67.2%; 76.6%)	50.3% (45.0%; 56.3%)	46.4% (40.5%; 53.1%)	273	77.5% (72.3%; 83.1%)	54.4% (48.0%; 61.6%)	51.6% (44.8%; 59.6%)

Type	Period	Stage	N at risk	Males Net Survival Probability 1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	Females Net Survival Probability 1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		III	340	69.4% (64.3%; 74.9%)	37.2% (31.8%; 43.5%)	26.3% (21.2%; 32.6%)	242	68.6% (62.7%; 75.0%)	32.8% (27.0%; 39.9%)	22.3% (17.0%; 29.2%)
		IV	656	29.5% (26.2%; 33.4%)	6.9% (5.1%; 9.5%)	3.3% (2.1%; 5.3%)	436	31.9% (27.7%; 36.7%)	9.1% (6.7%; 12.5%)	6.2% (4.2%; 9.2%)
		X/NA	278	32.2% (26.8%; 38.6%)	14.1% (10.0%; 19.8%)	9.8% (6.3%; 15.5%)	271	34.6% (29.1%; 41.3%)	11.7% (7.9%; 17.4%)	6.9% (3.9%; 12.2%)
	2019-2023	All	1,766	59.2% (56.8%; 61.6%)	37.6% (35.0%; 40.3%)	30.1% (26.9%; 33.8%)	1,254	56.4% (53.6%; 59.3%)	34.1% (31.1%; 37.4%)	28.4% (24.8%; 32.5%)
		I	335	85.1% (80.7%; 89.8%)	77.3% (71.2%; 83.9%)	70.3% (60.1%; 82.2%)	244	84.6% (79.4%; 90.1%)	70.8% (63.1%; 79.5%)	63.2% (52.7%; 75.8%)
		II	303	77.7% (72.7%; 83.1%)	59.0% (52.5%; 66.4%)	43.5% (34.9%; 54.2%)	227	70.2% (64.1%; 76.8%)	47.3% (40.3%; 55.6%)	40.0% (31.7%; 50.4%)
		III	307	71.5% (66.2%; 77.2%)	44.7% (38.4%; 51.9%)	34.5% (27.6%; 43.2%)	199	68.1% (61.5%; 75.3%)	42.6% (35.0%; 51.7%)	40.3% (31.8%; 51.0%)
		IV	681	38.3% (34.7%; 42.3%)	10.7% (8.3%; 13.7%)	6.7% (4.6%; 9.8%)	476	34.3% (30.2%; 38.9%)	9.2% (6.7%; 12.7%)	3.9% (2.1%; 7.4%)
		X/NA	140	31.2% (23.9%; 40.6%)	11.3% (6.5%; 19.6%)	9.2% (4.5%; 19.0%)	108	39.6% (30.7%; 51.0%)	15.8% (8.8%; 28.2%)	12.6% (5.8%; 27.4%)
NENs	2004-2008	All	74	59.6% (49.2%; 72.2%)	53.8% (42.8%; 67.6%)	54.3% (42.7%; 69.1%)	116	90.7% (85.1%; 96.8%)	84.3% (76.5%; 92.8%)	79.1% (69.7%; 89.9%)
		I	11	N<50	N<50	N<50	21	N<50	N<50	N<50
		II	1	N<50	N<50	N<50	1	N<50	N<50	N<50
		III	1	N<50	N<50	N<50	1	N<50	N<50	N<50
		IV	13	N<50	N<50	N<50	9	N<50	N<50	N<50
		X/NA	48	N<50	N<50	N<50	84	92.6% (86.4%; 99.3%)	89.9% (81.5%; 99.1%)	82.6% (71.6%; 95.4%)
	2009-2013	All	106	78.5% (70.6%; 87.4%)	70.1% (60.7%; 80.9%)	64.3% (53.7%; 76.9%)	151	88.5% (83.1%; 94.3%)	85.1% (78.2%; 92.6%)	81.1% (73.0%; 90.1%)
		I	28	N<50	N<50	N<50	53	96.6% (90.4%; 103.2%)	91.9% (81.6%; 103.5%)	91.7% (79.5%; 105.6%)
		II	14	N<50	N<50	N<50	7	N<50	N<50	N<50
		III	5	N<50	N<50	N<50	7	N<50	N<50	N<50
		IV	16	N<50	N<50	N<50	7	N<50	N<50	N<50
		X/NA	43	N<50	N<50	N<50	77	91.2% (84.4%; 98.4%)	89.5% (81.0%; 99.1%)	84.6% (74.5%; 96.1%)
	2014-2018	All	143	83.1% (76.8%; 90.0%)	78.2% (70.5%; 86.7%)	78.6% (69.9%; 88.4%)	180	92.4% (88.2%; 96.8%)	88.4% (82.8%; 94.4%)	86.9% (80.4%; 94.0%)
		I	40	N<50	N<50	N<50	65	98.4% (94.2%; 102.8%)	100.8% (95.5%; 106.3%)	104.2% (97.1%; 111.7%)

Type	Period	Stage	N at risk	Males Net Survival Probability 1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	Females Net Survival Probability 1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		II	18	N<50	N<50	N<50	15	N<50	N<50	N<50
		III	6	N<50	N<50	N<50	4	N<50	N<50	N<50
		IV	18	N<50	N<50	N<50	7	N<50	N<50	N<50
		X/NA	62	86.7% (77.7%; 96.7%)	83.0% (71.7%; 96.2%)	83.3% (69.7%; 99.6%)	89	92.4% (86.5%; 98.7%)	84.2% (75.7%; 93.5%)	80.7% (71.1%; 91.7%)
	2019-2023	All	167	90.8% (86.0%; 95.9%)	77.5% (69.7%; 86.0%)	73.4% (64.1%; 84.1%)	207	91.0% (86.9%; 95.3%)	90.9% (86.1%; 96.1%)	92.3% (86.3%; 98.6%)
		I	87	99.9% (96.6%; 103.3%)	93.0% (84.6%; 102.3%)	89.5% (78.2%; 102.5%)	124	98.1% (95.0%; 101.4%)	98.6% (94.0%; 103.5%)	99.6% (92.8%; 106.9%)
		II	24	N<50	N<50	N<50	16	N<50	N<50	N<50
		III	7	N<50	N<50	N<50	9	N<50	N<50	N<50
		IV	24	N<50	N<50	N<50	13	N<50	N<50	N<50
		X/NA	25	N<50	N<50	N<50	45	N<50	N<50	N<50
Other	2004-2008	All	75	32.1% (22.9%; 44.9%)	23.9% (15.6%; 36.6%)	23.0% (14.5%; 36.4%)	46	N<50	N<50	N<50
		I	7	N<50	N<50	N<50	4	N<50	N<50	N<50
		II	1	N<50	N<50	N<50	3	N<50	N<50	N<50
		III	6	N<50	N<50	N<50				
		IV	20	N<50	N<50	N<50	7	N<50	N<50	N<50
		X/NA	41	N<50	N<50	N<50	32	N<50	N<50	N<50
	2009-2013	All	48	N<50	N<50	N<50	57	29.7% (19.7%; 44.6%)	14.7% (7.6%; 28.6%)	11.4% (5.3%; 24.5%)
		I	1	N<50	N<50	N<50	7	N<50	N<50	N<50
		II	8	N<50	N<50	N<50	6	N<50	N<50	N<50
		III	3	N<50	N<50	N<50	1	N<50	N<50	N<50
		IV	10	N<50	N<50	N<50	20	N<50	N<50	N<50
		X/NA	26	N<50	N<50	N<50	23	N<50	N<50	N<50
	2014-2018	All	56	44.0% (32.3%; 60.0%)	33.0% (21.5%; 50.5%)	32.4% (20.2%; 52.0%)	53	37.6% (26.2%; 53.9%)	25.7% (15.4%; 42.9%)	23.9% (13.5%; 42.3%)

Type	Period	Stage	Males N at risk	Males Net Survival Probability 1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	Females N at risk	Females Net Survival Probability 1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		I	6 N<50		N<50	N<50	4 N<50		N<50	N<50
		II	5 N<50		N<50	N<50	4 N<50		N<50	N<50
		III	3 N<50		N<50	N<50	4 N<50		N<50	N<50
		IV	17 N<50		N<50	N<50	7 N<50		N<50	N<50
		X/NA	25 N<50		N<50	N<50	34 N<50		N<50	N<50
	2019-2023	All	65 38.8% (28.1%; 53.5%)		24.7% (14.1%; 43.2%)	14.8% (5.5%; 39.7%)	40 N<50		N<50	N<50
		I	8 N<50		N<50	N<50	4 N<50		N<50	N<50
		II	8 N<50		N<50	N<50	7 N<50		N<50	N<50
		III	3 N<50		N<50	N<50	1 N<50		N<50	N<50
		IV	26 N<50		N<50	N<50	16 N<50		N<50	N<50
		X/NA	20 N<50		N<50	N<50	12 N<50		N<50	N<50

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

6.1. Gastric cancer mortality: by region

6.1.1. Gastric cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Males																						
Belgium	0	0	0	0	0	1	3	3	2	7	15	29	33	54	59	65	53	56	23	5	408	8.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.8]	[0.8]	[0.5]	[1.8]	[3.8]	[7.2]	[9.1]	[17.6]	[22.3]	[37.3]	[40.6]	[72.1]	[81.9]	[91.7]	[7.2]	(7.3; 8.9)
Brussels	0	0	0	0	0	0	0	0	0	1	2	3	3	1	7	2	6	5	1	1	32	8.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.3]	[5.0]	[8.8]	[11.0]	[4.8]	[41.9]	[17.4]	[71.0]	[98.9]	[46.0]	[214.1]	[5.3]	(5.7; 12.0)
Flanders	0	0	0	0	0	1	2	2	1	4	9	14	21	35	33	44	38	36	17	3	260	8.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[1.0]	[1.0]	[0.5]	[1.9]	[3.8]	[5.7]	[9.5]	[18.6]	[20.4]	[38.5]	[44.1]	[69.6]	[92.8]	[83.8]	[7.9]	(7.2; 9.2)
Wallonia	0	0	0	0	0	0	1	1	1	2	4	12	9	18	19	19	9	15	5	1	116	7.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[0.9]	[0.9]	[1.6]	[3.2]	[9.6]	[7.8]	[18.4]	[22.0]	[39.2]	[25.0]	[71.6]	[66.0]	[71.1]	[6.5]	(6.2; 9.1)
Females																						
Belgium	0	0	0	0	0	0	2	4	9	4	9	15	11	11	35	33	35	34	25	13	240	3.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[1.1]	[2.4]	[1.1]	[2.3]	[3.7]	[3.0]	[3.4]	[11.8]	[15.5]	[18.9]	[25.1]	[37.7]	[67.6]	[4.1]	(3.2; 4.1)
Brussels	0	0	0	0	0	0	0	1	2	1	0	2	2	1	1	4	2	2	1	0	19	3.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.1]	[4.4]	[2.5]	[0.0]	[6.0]	[6.7]	[4.1]	[4.6]	[24.6]	[14.6]	[19.7]	[17.4]	[0.0]	[3.1]	(2.0; 5.3)

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Flanders	0	0	0	0	0	0	1	3	3	2	5	7	3	9	22	23	24	25	14	12	153	3.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[1.4]	[1.4]	[1.0]	[2.2]	[2.9]	[1.4]	[4.7]	[12.6]	[17.3]	[20.7]	[29.4]	[34.9]	[106.8]	[4.6]	(3.1; 4.4)
Wallonia	0	0	0	0	0	0	1	0	4	1	4	6	6	1	12	6	9	7	10	1	68	3.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.0]	[3.5]	[0.8]	[3.2]	[4.7]	[5.0]	[0.9]	[11.9]	[9.4]	[16.3]	[17.5]	[49.0]	[16.6]	[3.6]	(2.5; 4.1)

Note: Mortality, as registered with ICD-10 C16.

Belgian Cancer Registry

7.1. Gastric cancer mortality trends: by region

7.1.1. Gastric cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
Belgium	**N**	506	511	500	482	490	469	421	499	496	458	468	472	443	418	397	392	430	408		
	CR	9.9	10.0	9.7	9.3	9.4	8.9	7.9	9.3	9.2	8.4	8.5	8.6	8.0	7.5	7.1	7.0	7.6	7.2		
	ESR2013	14.2	14.0	13.5	12.5	12.5	11.7	10.4	12.1	11.8	10.7	10.6	10.2	9.7	8.8	8.3	8.0	8.6	8.1	-3.4 (-3.9; -2.9)	2004-2021
Brussels	**N**	44	43	34	32	38	41	34	33	43	41	38	31	50	38	31	31	36	32		
	CR	9.2	8.9	6.9	6.4	7.5	7.9	6.5	6.1	7.8	7.3	6.7	5.4	8.6	6.5	5.3	5.2	6.0	5.3		
	ESR2013	14.0	12.2	10.1	10.2	11.0	11.4	9.6	9.8	13.4	11.9	11.3	9.0	13.7	10.0	8.3	8.2	9.2	8.9	-1.7 (-3.1; -0.4)	2004-2021
Flanders	**N**	328	307	312	295	311	301	277	311	314	287	289	303	257	259	248	253	272	260		
	CR	11.1	10.3	10.4	9.8	10.2	9.8	9.0	10.0	10.0	9.1	9.1	9.5	8.0	8.0	7.7	7.8	8.3	7.9		
	ESR2013	15.3	14.3	14.1	12.5	12.8	12.7	11.5	12.3	12.1	10.9	10.7	10.6	8.8	8.8	8.3	8.3	8.7	8.2	-3.7 (-4.2; -3.1)	2004-2021
																				-3.6 (-6.2; -0.9)	2004-2008
																				-3.7 (-4.4; -3.0)	2009-2021
Wallonia	**N**	134	161	154	155	141	127	110	155	139	130	141	138	136	121	118	108	122	116		
	CR	8.2	9.8	9.3	9.3	8.4	7.5	6.5	9.0	8.1	7.5	8.1	7.9	7.7	6.9	6.7	6.1	6.8	6.5		
	ESR2013	12.1	14.0	13.4	13.0	12.3	10.1	8.7	12.1	10.3	10.0	10.0	9.6	10.3	8.4	7.9	7.2	8.1	7.7	-3.4 (-4.3; -2.4)	2004-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

Note: Mortality, as registered with ICD-10 C16.

7.1.2. Gastric cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
Belgium	**N**	338	317	328	319	310	282	302	311	311	284	276	268	270	270	244	238	251	240		
	CR	6.4	5.9	6.1	5.9	5.7	5.1	5.5	5.6	5.5	5.0	4.9	4.7	4.7	4.7	4.2	4.1	4.3	4.1		
	ESR2013	6.3	5.9	5.9	5.7	5.5	5.0	5.1	5.2	5.0	4.5	4.3	4.2	4.2	4.2	3.6	3.5	3.7	3.6	-3.4 (-3.8; -3.1)	2004-2021
Brussels	**N**	27	21	15	30	24	31	17	35	18	25	36	25	16	22	21	25	17	19		
	CR	5.2	4.0	2.8	5.6	4.4	5.6	3.0	6.1	3.1	4.2	6.0	4.1	2.6	3.6	3.4	4.1	2.7	3.1		
	ESR2013	4.9	4.1	3.1	5.8	4.2	6.2	3.1	6.8	3.3	4.8	6.5	4.9	3.0	4.1	4.0	5.0	3.1	3.7	-1.0 (-3.5; 1.6)	2004-2021
Flanders	**N**	218	205	221	181	188	182	197	180	199	172	174	158	171	169	138	159	148	153		
	CR	7.1	6.7	7.2	5.8	6.0	5.8	6.2	5.6	6.2	5.3	5.4	4.8	5.2	5.1	4.2	4.8	4.4	4.6		
	ESR2013	7.2	6.7	7.0	5.5	5.8	5.4	5.7	5.1	5.4	4.6	4.6	4.2	4.4	4.4	3.4	3.9	3.5	3.8	-4.0 (-4.6; -3.4)	2004-2021
Wallonia	**N**	93	91	92	108	98	69	88	96	94	87	66	85	83	79	85	54	86	68		
	CR	5.3	5.2	5.2	6.1	5.5	3.9	4.9	5.3	5.2	4.8	3.6	4.6	4.5	4.3	4.6	2.9	4.6	3.6		
	ESR2013	5.3	5.2	5.0	6.0	5.3	3.8	4.7	5.0	4.7	4.2	3.2	4.1	4.1	3.9	4.0	2.5	4.1	3.3	-3.0 (-4.4; -1.6)	2004-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

Note: Mortality, as registered with ICD-10 C16.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2021.

Mortality is reported by main group of ICD-10 classification.

Recommended reference: Cancer Fact Sheets 2023, Belgian Cancer Registry (BCR), 2025